Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned an average rating of “Buy” from the sixteen analysts that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $89.00.
A number of research firms have commented on SAGE. Needham & Company LLC reduced their price objective on shares of Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a research note on Wednesday, September 13th. Royal Bank of Canada began coverage on shares of Sage Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $117.00 price objective for the company. Chardan Capital reaffirmed a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, September 13th. HC Wainwright upped their price objective on shares of Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Finally, BidaskClub lowered shares of Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd.
A number of institutional investors and hedge funds have recently modified their holdings of SAGE. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Sage Therapeutics by 11.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 138 shares in the last quarter. Turner Investments LLC bought a new position in Sage Therapeutics during the second quarter valued at approximately $159,000. Dubuque Bank & Trust Co. bought a new position in Sage Therapeutics during the second quarter valued at approximately $167,000. Canada Pension Plan Investment Board bought a new position in Sage Therapeutics during the second quarter valued at approximately $175,000. Finally, Ameritas Investment Partners Inc. bought a new position in Sage Therapeutics during the first quarter valued at approximately $180,000.
Sage Therapeutics (SAGE) traded down 2.07% during trading on Friday, hitting $61.40. 723,168 shares of the stock were exchanged. Sage Therapeutics has a 12-month low of $38.30 and a 12-month high of $90.80. The firm’s market cap is $2.30 billion. The stock’s 50-day moving average price is $80.79 and its 200-day moving average price is $74.87.
Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same quarter in the prior year, the firm earned ($1.08) EPS. On average, equities analysts expect that Sage Therapeutics will post ($7.38) EPS for the current year.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.